ABL SH3 mutant inhibits BCR-ABL activity and increases imatinib sensitivity by targeting RIN1 protein in CML cell
Xin Liu(National Clinical Research Center for Digestive Diseases), Wenli Feng(Children's Hospital of Chongqing Medical University), Liang-xue Wen(Chongqing Medical University), Fang Wang(Shanghai Medical College of Fudan University), Hui Li(Shanghai Stomatological Hospital), Qing Xiao(The Affiliated Yongchuan Hospital of Chongqing Medical University), Yajuan Li(Ningbo University), Zhenglan Huang(Chongqing Medical University), Kun Tao(Shanghai Tenth People's Hospital), Weixi Cao, Miao Gao(Chongqing Medical University)
Cited by 3
Related Papers
Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates
|Chemistry & Biology|2013|498
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> Mutations
|Cancer Discovery|2017|457
Conductive Microporous Covalent Triazine‐Based Framework for High‐Performance Electrochemical Capacitive Energy Storage
|Angewandte Chemie International Edition|2017|251